A Multi-Asset Product Portfolio of Chemotherapeutics
We employ a drug discovery and development approach that allows us to efficiently design, research and advance drug candidates. In two years, we have successfully advanced our lead PDC, iopofosine into multiple Phase 2 clinical trials. Additionally, we have initiated three collaborations and two proprietary programs that are rapidly progressing toward clinical trials.
Explore Our PipelineAdvancing Innovation in Targeted Therapies
With the challenges that have faced other targeted therapeutic approaches, we have focused on developing the next generation of targeted therapies leveraging our PLE platform technology. We combine knowledge of targeting specificity, uptake and intracellular trafficking, and novel linker chemistry and release mechanisms to allow both a greater diversity in warhead delivery and potentially greater efficacy.
View Our TechnologyStock Information
IR Contact Information
Company Information
Cellectar Biosciences, Inc.
100 Campus Drive, Suite 207
Florham Park, NJ 07932
T: 608-441-8120
investors@cellectar.com
Investor Relations
Investor Contact
investors@cellectar.com
Business Development
Contact Information
businessdevelopment@cellectar.com
Social Media
Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.